Disopyramide pharmacokinetics and bioavailability
Mervyn Eadie
British Journal of Clinical Pharmacology, 1978
View PDFchevron_right
Quantitative analysis of the disopyramide concentration-effect relationship
Nick Holford
British Journal of Clinical Pharmacology, 1980
View PDFchevron_right
Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters
Jorma Ahokas
Journal of pharmacological methods, 1982
View PDFchevron_right
Disopyramide: Serum level and arrhythmia conversion
Andreas Niarchos
American Heart Journal, 1976
View PDFchevron_right
Gas—liquid chromatographic method for the routine estimation of disopyramide in plasma or serum
Atholl Johnston
Journal of Chromatography A, 1978
View PDFchevron_right
Binding of disopyramide to α1-acid glycoprotein in plasma measured by competitive equilibrium dialysis
Jorma Ahokas
Journal of Pharmaceutical Sciences, 1984
View PDFchevron_right
Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects
Karin Schenck-gustafsson
Clinical Pharmacology and Therapeutics, 1985
View PDFchevron_right
Simple high-performance thin-layer chromatography method for the determination of disopyramide and its mono-N-dealkylated metabolite in serum
Etienne Grandjean
Journal of Chromatography B: Biomedical Sciences and Applications, 1981
View PDFchevron_right
The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study
Charles Pollick
Circulation, 1982
View PDFchevron_right
Cardiovascular Collapse Associated with Disopyramide Therapy
Rolando Gonzalez
Chest, 1981
View PDFchevron_right
Total and free disopyramide by fluorescence polarization immunoassay and relationship between free fraction and alpha-1 acid glycoprotein
Alex Pappas
Clinica Chimica Acta, 1987
View PDFchevron_right
Simultaneous analysis of disopyramide and quinidine in plasma by high-performance liquid chromatography
Jorma Ahokas
Journal of chromatography, 1980
View PDFchevron_right
?Normal? response of the QT interval and QT dispersion following intravenous injection of the sodium channel blocker disopyramide: Methodological aspects
Lennart Bergfeldt
Cardiovascular Drugs and Therapy, 1995
View PDFchevron_right
Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method
David Juan
Clinical Pharmacology and Therapeutics, 1989
View PDFchevron_right
Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer
Daniele Ouellet
Cancer Chemotherapy and Pharmacology, 2000
View PDFchevron_right
Pharmacokinetic studies of DISIDA disposition
Peter Fabri
European Journal of Nuclear Medicine, 1988
View PDFchevron_right
Applied Clinical Pharmacokinetics
Brian Byrd
View PDFchevron_right
Evaluation of Pharmacokinetic and Pharmacodynamic Profiles and Tolerability After Single (2.5, 5, or 10 mg) and Repeated (2.5, 5, or 10 mg BID for 4.5 days) Oral Administration of Ivabradine in Healthy Male Korean Volunteers
Keith Wesnes
Clinical Therapeutics, 2013
View PDFchevron_right
PHARMACOKINETICS- CLINICAL PHARMACOLOGY
magendira mani vinayagam
View PDFchevron_right
Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats
HITOSHI SATO
Journal of Pharmaceutical Sciences, 1999
View PDFchevron_right
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
Sara Giovani
Journal of Clinical Medicine, 2023
View PDFchevron_right
Pharmacokinetics : Interactions of New Drugs and the Human Body
Barry Bleidt
Drugs and the Pharmaceutical Sciences, 1996
View PDFchevron_right
An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs
Dirk K F Meijer
Journal of Pharmacokinetics and Biopharmaceutics, 1996
View PDFchevron_right
PII-59Population pharmacokinetic analysis of AVP-923 (30 mg dextromethorphan and 30 mg quinidine)
Jean-Francois Marier
Clinical Pharmacology & Therapeutics, 2006
View PDFchevron_right
N-Acetylprocainamide kinetics and clinical response during repeated dosing
Roger Jelliffe
Clinical Pharmacology and Therapeutics, 1982
View PDFchevron_right
Preliminary Pharmacokinetics and Pharmacodynamics 28
Ali Najam
View PDFchevron_right
Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate‐release oral formulation in healthy volunteers
John Grundy
Pulmonary circulation, 2020
View PDFchevron_right
Variability in Response to Drugs
Mary Mihalyo
Journal of Pain and Symptom Management, 2015
View PDFchevron_right
Complementary Pharmacokinetic Measures
Krishna Devarakonda
View PDFchevron_right
Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults
Alan Pollock
Antimicrobial Agents and Chemotherapy, 1982
View PDFchevron_right
Value of therapeutic drug level monitoring and unbound (free) levels
Kenny Chan
Seizure, 2008
View PDFchevron_right
Multiple Peaking Phenomena in Pharmacokinetic Disposition
Dion Brocks, Dr. Jaime A Yanez, Ph.D., Neal Davies
Clinical Pharmacokinetics, 2010
View PDFchevron_right
The influence of acidosis on the myocardial uptake and electrocardiographic effects of disopyramide
Roberto Padrini
European Journal of Pharmacology, 1989
View PDFchevron_right
Journal of Pharmacy and Pharmacology (Volume 3, Number 10) October 2015.pdf
Oksana Tryhubchak
View PDFchevron_right
Comparison of Oral and Oral Sustained-Release Rilmenidine in Healthy Volunteers and Correlation with In Vitro Sustained-Release Properties
Saco de Visser
Clinical Drug Investigation, 2001
View PDFchevron_right